These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22309606)

  • 1. Ranibizumab for age-related macular degeneration.
    Dhoot DS; Kaiser PK
    Expert Opin Biol Ther; 2012 Mar; 12(3):371-81. PubMed ID: 22309606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranibizumab: Phase III clinical trial results.
    Rosenfeld PJ; Rich RM; Lalwani GA
    Ophthalmol Clin North Am; 2006 Sep; 19(3):361-72. PubMed ID: 16935211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of ranibizumab trials for neovascular age-related macular degeneration.
    Patel RD; Momi RS; Hariprasad SM
    Semin Ophthalmol; 2011 Nov; 26(6):372-9. PubMed ID: 22044335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.
    Jiang S; Park C; Barner JC
    J Clin Pharm Ther; 2014 Jun; 39(3):234-9. PubMed ID: 24635444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.
    Fong AH; Lai TY
    Clin Interv Aging; 2013; 8():467-83. PubMed ID: 23766636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.
    Abraham P; Yue H; Wilson L
    Am J Ophthalmol; 2010 Sep; 150(3):315-324.e1. PubMed ID: 20598667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
    Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
    Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
    Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden.
    Haller JA
    Ophthalmology; 2013 May; 120(5 Suppl):S3-7. PubMed ID: 23642784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.
    Frampton JE
    Drugs Aging; 2013 May; 30(5):331-58. PubMed ID: 23539234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A safety evaluation of ranibizumab in the treatment of age-related macular degeneration.
    Gibson JM; Gibson SJ
    Expert Opin Drug Saf; 2014 Sep; 13(9):1259-70. PubMed ID: 25091039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab for the treatment of neovascular AMD.
    Kaiser PK; Do DV
    Int J Clin Pract; 2007 Mar; 61(3):501-9. PubMed ID: 17313620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.
    Ohr M; Kaiser PK
    Expert Opin Pharmacother; 2012 Mar; 13(4):585-91. PubMed ID: 22300011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes.
    Canton VM; Quiroz-Mercado H; Velez-Montoya R; Lopez-Miranda MJ; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
    Ophthalmic Surg Lasers Imaging; 2011; 42(6):468-73. PubMed ID: 21830747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.